GC Cell Holds 'GC Cell Customer Day 2026'

Sharing CDMO Competitiveness and Global Business Strategies

GC Cell announced on April 9 that it held the 'GC Cell Customer Day 2026' on the 8th, inviting advanced biopharmaceutical development institutions and companies.

This event was organized to introduce GC Cell's CDMO (Contract Development and Manufacturing Organization) business competitiveness and differentiated GMP infrastructure, as well as to share business strategies, regulatory trends, and investment trends in the global cell and gene therapy market.

GC Cell hosted the 'GC Cell Customer Day 2026' on the 8th, inviting advanced biopharmaceutical development institutions and companies. GC Cell

During the event, a variety of presentations were given focusing on CDMO service capabilities, regulatory affairs (RA) strategies, global business directions for cell and gene therapies (CGT), and regulatory and investment trends related to advanced biopharmaceuticals. In addition, a networking program with major clients and partners was held, along with a tour of GC Cell's GMP facilities, providing participants with the opportunity to directly observe the production infrastructure and operational capabilities.

GC Cell has built customized solutions and a stable production infrastructure based on its CDMO capabilities to provide end-to-end services from development and clinical trials to commercialization of cell and gene therapies. In particular, the company is strengthening its position as an optimal partner for advanced biopharmaceutical development through global-level GMP facilities and quality systems.

Through this event, GC Cell expanded its touchpoints with potential customers and enhanced technical credibility by sharing real project execution experience and global business strategies, while also working to raise awareness of its CDMO business.

Sungyong Won, CEO of GC Cell, said, "This event was a meaningful opportunity to share GC Cell's CDMO capabilities and global business strategies directly with customers and partners. We will continue to provide optimal solutions throughout the entire cycle of advanced biopharmaceutical development based on differentiated technologies and GMP infrastructure and will continuously expand our global collaboration ecosystem."

This content was produced with the assistance of AI translation services.